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Congenital myasthenic syndromes (CMS) are clinically and genetically heterogeneous inherited disorders characterized by impaired
neuromuscular transmission. Mutations in the acetylcholinesterase (AChE) collagen-like tail subunit gene (COlQ) cause recessive forms
of synaptic CMS with end plate AChE deﬁciency. We present data on 15 COLQ -mutant CMS carrying 16 diﬀerent mutations (9 novel
ones identiﬁed) followed-up for an average period of 10 years. The mean age at the ﬁrst examination was 19 years old (range from 3 to
48). We report relapses during short or long-term periods characterized by worsening of muscle weakness sometimes associated with
respiratory crises. All the relapses ended spontaneously or with 3–4 DAP or ephedrine with no residual impairment. The triggering
factors identiﬁed were esterase inhibitors, eﬀort, puberty or pregnancy highlighting the importance of hormonal factors. There was
no genotype–phenotype correlation. At the end of the follow-up, 80% of patients were ambulant and 87% of patients had no respiratory
trouble in spite of severe relapses.
 2011 Elsevier B.V. All rights reserved.
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Congenital myasthenic syndroms (CMS) are clinically
and genetically heterogeneous inherited disorders in which
the safety margin of neuromuscular transmission is
compromised [1,2]. Fourteen CMS-related genes have been0960-8966/$ - see front matter  2011 Elsevier B.V. All rights reserved.
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E-mail address: isabelle.wargon@psl.aphp.fr (I. Wargon).described so far, coding for proteins involved in
neuromuscular transmission [2–6]. However, it is estimated
that half of the CMS remain genetically unidentiﬁed. The
syndromes are classiﬁed according to the localization of
the corresponding defect at the neuromuscular junction as
presynaptic, synaptic basal-lamina associated and postsyn-
aptic [1,2].
Recessive synaptic CMS caused by acetylcholinesterase
(AChE) deﬁciency were ﬁrst described in 1977 [7]. Since
then, few cases of partial or complete deﬁciency of the
enzyme have been reported [8]. Absence of AChE in the
synaptic space extends the lifetime of acetylcholine and
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by increasing the duration of the end-plate current [7]. This
outlasts the refractory period of the muscle ﬁbers and
evokes a desynchronized compound muscle action poten-
tial (CMAP) following the electrical stimulation of the
nerve-muscle complex with the appearance of a so-called
‘double CMAP’ [7]. The collagenic tail of endplate AChE
or COLQ is composed of (i) a N-terminal proline-rich
region attachment domain (PRAD) linked to the catalytic
subunits, (ii) a triple helical homotrimeric collagen-like tail
subunit structure, and (iii) a C-terminal region enriched in
charged residues and cysteines allowing for the anchoring
of the enzyme into the basal lamina. COLQ plays an
important structural role at neuromuscular junctions by
anchoring and accumulating AChE in the extracellular
matrix [11]. Thirty diﬀerent COLQ mutations have been
described to date [12]. The majority of them are null muta-
tions (frameshift, splice and nonsense mutations) which
truncate the protein distally to PRAD [1,13,14]. The
reported missense substitutions are located in the C-termi-
nal region and potentially aﬀect the insertion of the mole-
cule in the membrane [4]. Clinically, patients harbouring
COLQ mutations are aﬀected from an early age with a pro-
gressive muscle weakness and a respiratory insuﬃciency.
Associated slow pupillary light response, double CMAPs
and no beneﬁcial eﬀect or even worsening of the muscle
weakness after administration of AChE inhibitors are con-
sidered as diagnostic clues pointing to COLQ-related-CMS
[14]. Here, we present the clinical and molecular genetics
ﬁndings of 15 patients with COLQ mutations for an aver-
age period of 10 years. The long-term follow up of the con-
siderable size of the group studied enables us to further
describe the phenotypic and genotypic spectrum of end
plate AChE deﬁciency. We observed a large clinical heter-
ogeneity except the permanence of the double CMAP on
EMG. Symptoms strongly ﬂuctuated over time (including
daily, weekly, monthly or even yearly changes). Worsening
of muscle weakness was noticed during relapses in the short
or long-term. Respiratory crises with bulbar signs were
only present in relapses lasting for months or years. All
the relapses ended either spontaneously or with 3–4 DAP
or ephedrine without residual impairment. Triggering fac-
tors identiﬁed were hormonal, eﬀort or esterase inhibitors.2. Patients and methods
Fifteen patients (8 males, 7 females) from 14 unrelated
families were followed up over a mean period of 10 years
(range from 1 to 23 years). Patients 1 and 4 were previously
reported [15]. The mean age at the ﬁrst examination was
19 years old (range from 3 to 48). Clinical examinations were
performed by neurologists [I.W., B.E. and T.S. at the Myol-
ogy Institute of Pitie´-Salpeˆtrie`re Hospital (13 patients), T.K.
at Lausanne University Hospital (1 patient) and S.N. at
Teheran University Hospital (1 patient)] during routine
medical check-ups. Six patients (patients 2, 5, 9, 10–12 onTable 1a and b) were born from consanguineous marriages.
Written informed consent was obtained from all patients or
their legal representatives in accordance with the study pro-
tocol approved by the ethics committee of the Pitie´-
Salpe´trie`re Hospital. All patients, but one, underwentmotor
nerve conduction studies performed on the ulnar, peroneal
and facial nerves. Repetitive stimulation at 3 Hz was carried
out on the ulnar, spinal, facial, radial and peroneal nerves
andCMAPswere recorded on abductor digiti minimi, trape-
zius, orbicularis oculi, tibialis anterior and the anconeus
muscles, respectively. Muscle biopsies were processed in 11
cases (patients 1–7, 11–13, 15) according to standard histo-
logical, histochemical, and immunohistochemical tech-
niques [16–18]. Venous blood samples were obtained from
the patients and their unaﬀected relatives. Genomic DNA
was isolated using a blood DNA extraction kit according
to the manufacturer’s recommendations (Puriﬁcation kit,
Promega, Mannheim, Germany).
Identiﬁcation of COLQ mutations was performed using
direct sequencing on PCR products. All 17 exons and their
ﬂanking intronic regions were PCR ampliﬁed and sequenced
using the Terminator v3.3 Cycle Sequencing Kit then run on
the ABI3730 capillary electrophoresis system (Applied
Biosystems). Electropherograms were analyzed using the
SeqScape software (Applied Biosystem) and sequences
were compared to reference sequences (NM_005677.3).
The Alamut (www.interactive-biosoftware.com) software
helped us to interpret the pathogenicity of variants found.3. Results
3.1. Clinical phenotype
The clinical features of the patients are detailed in Table
1a (Fig. 1). The disease manifested at a mean age of
13 months (range from birth to 10 years). At birth, the only
constant clinical sign was muscular hypotonia (5 cases).
Other signs observed at birth included ptosis (4 cases) with
or without ophthalmoparesis and bulbar signs as respira-
tory distress (2 cases) and dysphagia (3 cases). However,
those clinical signs are not speciﬁc to birth since they have
also been observed later on at the onset of the disease, and/
or during relapses for bulbar signs. The age at which
patients ﬁrst walked was only delayed in 4 cases. During
childhood, in all cases, proximal weakness muscle, aﬀecting
both upper and lower limbs, emerged and led to frequent
falls. Additional clinical signs observed during childhood
included hypoplasia of superior thorax and microtesticles
(patients 8, 10), ankle contractures (patients 2, 3, 5), hip
(patient 2) or knee (patient 15) retractions. During late
childhood, scoliosis or hyperlordosis developed in 7 cases
(patients 4, 6, 7, 10, 12–14). Arthrogryposis was not found
in any of the patients. Pains, described as cramps or myal-
gia, were often reported and appeared to be triggered by
exertion, the end of the day, cold winter or hot summer.
Dysaesthesia was reported in patient 15.
Table 1a
Clinical data of the 15 patients with COLQ mutation.
Patient Gender Ethnic
origin
Age of
onset
(months)
Age of
walking
(months)
Ophthalmoparesis
/Ptosis/FW/
Dysphagia
Proximal
/axial/
distal/
neck
weakness
SPRL Follow
up
Pains Respiratory
crises/NIV/
tracheotomy
Relapses
over
months/
years
besides
hormonal
factors
Aggravation
during
puberty/
pregnancy or
deliver
Clinical
status at
the end
of the
follow
up:
Walton
scale
[28]/
NIV
1 F French 6 12 +/+//+ +/+/+/+ + 13 + +/+/ /+;+;+ +/* VIII/+
2 M Turkish 120 13 /// +/+/+/+  7   / +/* I/
3 F French/
Spanish
Birth 16 /// +/-/+/+  13 +  / +/+ I/
4 F French Birth 24 +/+/+/+ +/+/+/+ + 23 +  /+ +/* I/
5 F French 36 15 ///+ +///+  9 +  +/+ ;+ +/+ I/
6 M Italian 10 10 /// +/+//  12 +  /+ +/* II/
7 F Portuguese Birth 15 +/+/+/+ +/+/+/+ + 7 + +/+/+ +/+ +/+ I/
8 M Filipino 24 16 +/+/+/ +/+ /+/
+
 6 + +/+/+ / +/* I/
9 M Kurdish 24 14 +/+/+/+ +/+/+/+  6 +  / +/* I/
10 M Turkish birth 34 +/+/+/+ +/+/+/+  5 + +/+/+ /+ */* VI/+
11 M Spanish 72 15 /+// +///  1   nd +/* nd
12 F Moroccan 24 13 /+// +/+//+ nd 1 +  /+ +/* VI/
13** F French 24 24 /// +/+//+  20 + +/+/ /+ +/+ I/
14** M French 13 13 ///+ +/+//+  13   /+ /* I/
15 M French Birth 18 +/+// +/+//+  3 +  / */* III/
* Not applicable; Gardner-Medwin and Walton scales [28]: grade 0: normal; grade I: unable to run freely; grade II: diﬃculty walking on tiptoes; grade III:
climbing stairs with banister; grade IV: presence of Gowers’ sign; grade V: unable to rise from the ﬂoor; grade VI: unable to climb stairs; grade VII: unable
to rise from a chair; grade VIII: unable to walk without assistance; grade IX: unable to sit, drink or eat without assistance.
** Brother and sister. FW: facial weakness; SPRL: slow pupillary response to light; nd: no data; NIV: non invasive ventilation.
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We observed both short- and long-term clinical ﬂuctua-
tions from our cohort.
3.2.1. “Short-term ﬂuctuations”: day or week
All patients experienced day-time ﬂuctuations of the
symptoms highly dependent on exercise. Patient 6 experi-
enced two episodes of tetraparesis during one hour after
rambling at the age of 17. Patient 2 could hardly move
his mouth after having chewed gum all day long at the
age of 18. All patients reported worsening of muscle weak-
ness at the end of the day and/or over a 2 or 3 days period.
In 5 cases, cold temperatures exacerbated weakness
(patients 3, 4, 6, 10, 12). Heat with humidity had the same
eﬀect in 4 cases (patients 6, 7, 13, 15). All women, but one
(patient 13), reported worsening of their symptoms during
either premenstrual period, menstruations or even after the
end of the cycle.
In addition to day-time ﬂuctuations observed in the
whole cohort, 3 cases (patients 2, 3, 10) exhibited muscle
weakness that lasted for several weeks.
However, these short-term ﬂuctuations (including days
and weeks’ ones), did not require any therapeutic treatment
in any of the patients.3.2.2. “Long-term ﬂuctuations”: month or year
All women of our cohort who had pregnancy triggered
relapses whatever the way of delivery (eutocia or caesarean
section). These relapses started during the last months of
pregnancy and/or the post-partum phase (starting 5 to
10 days after the delivery), lasted from 3 to 8 months and
recovered spontaneously without treatment, except for
patient 7. In all patients, relapses were characterized by
worsened weakness aﬀecting the lower limbs. In two cases
(patients 5 and 7), this muscular impairment was extremely
severe, requiring the use of a crutch or even a wheelchair,
and was associated with dysphagia. In addition, patient 7
suﬀered an acute respiratory distress leading to assisted
ventilation and tracheotomy. The introduction of ephed-
rine allowed her to recover from this relapse without resid-
ual impairment.
One or several relapses over a 2 or 3 years period,
characterized by dysphagia, dyspnoea or worsening of
muscle weakness, have been noticed in 9 cases (patients
1, 4–6, 9, 11–14). Intense eﬀort (patient 6) and esterase
inhibitors in 2 cases (patients 1, 7) were the triggering
factors identiﬁed. Two patients (patients 1, 7) were bed-
ridden during 5–12 months, during such relapses. Trache-
otomy, assisted ventilation and gastrostomy were
necessary in patient 10.
A B C D
Fig. 1. Patients with Col Q mutations. AB: Patient 1. At the age of 48 she can climb stairs using a bannister before progressive worsening. She is actually
severely aﬀected. She is unable to walk without assistance and needs non invasive ventilation. CD: Patient 5. At the age of 33 she is unable to run freely
between relapses. She is actually mildly aﬀected.
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on average 5 years has been observed in the whole
cohort around puberty (except for patients 10 and 15
who were followed up before puberty). Symptoms sponta-
neously ended at a mean age of 18 years without any med-
ication. A wheelchair was necessary in one case (patient
12). No bulbar sign or acute respiratory distress ever
occurred.
3.2.3. “Progressive worsening”
In patient 1, after relapses reported until the age of
48 years old (see above), the disease progressed gradually
over 10 years characterized by a worsening of muscle
weakness requiring a wheelchair, and dyspnoea needing
assisted ventilation at home. When ephedrine was initiated,
dysphagia and dysphonia resolved completely. Assisted
ventilation was necessary for 12 h instead of 14 h a day
and a crutch was adequate for mobility indoors.
3.2.4. Diagnostic delay
Diagnostic delay was delayed in the whole cohort up to
a mean age of 23 years (range from 3 to 48 years) after
symptom onset. Three diﬀerent aetiologies have been sug-
gested as follows:
(i) Seronegative auto-immune myasthenia was sug-
gested in 6 cases (patients 2, 6–9, 15). Mean symp-
tom onset was 30 months (from birth to
120 months). Muscle biopsy, when it was performed,
was considered normal in 3 cases (patients 2, 6, 7).
Steroids tried in 2 cases (patients 7, 9) were stopped
after 3 months because of further impairment of
symptoms.
(ii) Metabolic myopathy was the initial diagnosis in 4
cases (patients 1, 3, 4, 13). Mean symptom onset
was 7 months (from birth to 24 months). Treatment
with L-Carnitine and Coenzyme Q10 was given for
2 to 16 years. A subjective eﬀect was found in 2 cases
(patients 3, 4). Muscle biopsy showed lipid accumula-
tion in 2 cases (patients 3, 13).(iii) Congenital myopathy was the ﬁrst diagnosis in 2
cases (patients 10, 12). Mean symptom onset was
12 months (birth to 24 months). Severe symptoms
were observed: assisted ventilation, tracheostomy
and gastrostomy at the age of 6 months in patient
10, whereas a wheelchair was required from age 10
to 17 years in patient 12.
3.2.5. Response to treatment
Acetylcholinesterase inhibitor treatment exacerbated
symptoms or was ineﬀective in 11 cases. It potentially trig-
gered severe relapses in 2 cases (patients 1, 7).
3, 4-Diaminopyridine (DAP) prescribed in 8 cases led to
an improvement of the muscle weakness in 3 cases with
30–60 mg daily.
Since ephedrine is not widely available in France, this
was only administered in 3 cases where it had remarkable
beneﬁts, improving muscle weakness in all cases and allow-
ing one case to be weaned oﬀ ventilation (patient 7). Flu-
oxetine, administrated in one patient (patient 8),
improved both fatigability and muscle weakness. Hor-
monal contraception prevented the deterioration of symp-
toms during menstruation in patient 4 whereas an
improvement of the muscle weakness was noticed with
menopause in patient 3.
3.2.6. Disease progression
At the end of follow-up, walking was possible without
aids in 11 cases. An assistance or a crutch in 2 cases and a
wheelchair in another case were reported. Assisted ventila-
tion was required in 2 cases (12 h daily for patient 1 and
20 min daily for patient 10). Complementary nocturnal feed-
ing by gastrostomy was necessary in one case (patient 10).
3.2.7. Laboratory, electromyography and muscle biopsy
studies
Creatine kinase level was normal in all individuals
tested. Antibodies against Ach receptors or against mus-
cle-speciﬁc receptor-tyrosine kinase (MuSK) were negative
in the serum.
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response following 3 Hz repetitive nerve stimulation was
found in 95% of the 40 tested muscles in the whole cohort.
The mean decremental response on ulnar nerve was 20%
(range: 10–36%) recorded in 12 cases. But the most signif-
icant decremental response was obtained by stimulating the
radial nerve (mean value 52%, range: 24–77%) in 6 cases. A
double CMAP of abductor digiti minimi was also found in
all patients after single stimulation of the ulnar nerve.
Needle electromyography showed a myogenic pattern
without spontaneous activity.Table 1b
Biopsy and mutation results of the 15 patients.
Patient Muscle biopsy AChE at the end
plates
Mutation (protein a
cDNA level)
1 N/Predominance of type
I ﬁbers and atrophy of
type II ﬁbers
ND c.1071G>A/p.Arg
(c.706C>T).
2 N ND p.Cys427Cys (c.128
Homozygote
3 N/ predominance ﬁbers I
and lipid accumulation
in ﬁbers II
ND p.Tyr430Ser (c.1289
Homozygote
4 Predominance of type I
ﬁbers and atrophy of
type II ﬁbers
Abnormally low c.107–1G>A c.788in
5 Predominance of type I
ﬁbers and atrophy of
type II ﬁbers
Abnormally low p.Tyr430Ser (c.1289
p.Cys427Cys (c.128
6 N ND p.Ile446Thr (c.1337
c.1082delC
7 N/Predominance of type
I ﬁbers and atrophy of
type II ﬁbers
ND c.157dup Homozyg
8 ND ND p.Pro59Ser (c.175C>
p.Cys451Ser (c.1351
9 ND ND p.Arg227X (c.679C>
Homozygote
10 ND ND p.Trp148X (c.444G
Homozygote
11 Predominance of type I
ﬁbers and atrophy of
type II ﬁbers
Abnormally low p.Tyr430Ser (c.1289
Homozygote
12 Predominance of type I
ﬁbers
ND p.Arg410Trp (c.122
Homozygote
13** Predominance of type I
ﬁbers and lipid
accumulation in ﬁbers II
ND c.219+1G>C p.Arg
(c.1019G>A)
14** ND ND c.219+1G>C p.Arg
(c.1019G>A)
15 Predominance of type I
ﬁbers
ND p.Thr441Ala (c.1321
c.1082del
N = “normal; : absence of clinical eﬃciency; + = clinical improvement.
* Not administrated; ND: no done.
** Brother and sister.Muscle biopsy (Table 1b) was performed in 11 cases. It
was ﬁrst considered as normal in 5 cases leading to a
second biopsy in 3 cases. Predominance of type I ﬁbers
and atrophy of type II ﬁbers was reported in 7 cases. Pre-
dominance of type I ﬁbers with lipid accumulation in type
II ﬁbers was observed in 2 cases (Fig. 2). In 3 cases, the
AChE activity was studied and was abnormally low,
whereas the density of receptors appeared normal. In addi-
tion, the end plates were much smaller than those in con-
trol muscles. Silver impregnation of nerve terminals on
muscle sections showed a normal aspect of the terminal-nd Consequence of mutations Treatment by
acetylcholinesterase
inhibitors/ 3–4 DAP/
ephedrine
236X Splice mutation Non sense
mutation
//+
1C>T) Creation of a cryptic donor splice
site in exon 16 leading to 19
exonic nucleotides deletion
/+/*
A>C) Missense substitution //*
sC Splice mutation Frame shift
mutation
*/*/*
A>C)
1C>T)
Missense Substitution. Cryptic
splice leading to 19 Nt deletion
*/+/*
T>C) Missense substitution Frame
shift mutation
(p.Pro361LeufsX65)
/*/*
ote Frame shift mutation
(p.Leu53ProfsX81)
//+
T)
T>A)
Missense substitution /*/*
T) Nonsense Mutation //+
> A) Nonsense Mutation //*
A>C). Missense substitution /*/*
8C>T) Missense mutation */*/*
340His Splice mutation Missense
substitution
/*/*
340His Splice mutation Missense
substitution
*/*/*
A>G) Missense substitution Frame
shift mutation
(p.Pro361LeufsX65)
/+/*
Table 2
Comparison of our results with the literature [12].
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folds showed marked degenerative changes.Clinical symptoms or EMG ﬁndings Literature
(%)
Our study
(%)
Proximal muscle weakness 100 100
Lack of beneﬁt from ACHE inhibitors 100 100
Decrement 89 100
Onset at birth or during the ﬁrst year of
life
81 47
Ptosis 81 53
Delayed motor milestones 77 27
Double CMAP 66 100
Facial weakness 63 33
Axial muscle weakness 63 80
Ophthalmoparesis 59 47
Respiratory crises 45 33
Dysphagia and/or chewing diﬃculties 40 47
Slow pupillary light response 25 20
Pains nd 873.2.8. Genetic analysis: Table 1b
In all patients, the molecular defect responsible for the
disease was identiﬁed by sequencing the 17 exons of COLQ
gene and their boundaries.
Among the 14 unrelated patients, 16 diﬀerent mutations
were identiﬁed. Nine mutations were novel ones including,
six null allele c.1071G>A, c.157dup, c.219+1G>C,
c.788insC, c.1082delC, c.1281C>T, and three missense sub-
stitutions p.Pro59Ser, p.Thr441Ala and p.Ile446Thr. Seven
homozygous mutated patients suggest a familial consan-
guinity [2,3,7,9–12] including four nonsense mutations
and two missense substitutions. The eight remaining
patients are heteroallelic for missense and/or null muta-
tions. Interestingly, a novel c.1281C>T mutation was dis-
covered. This substitution is predicted to lead to the
synonymous substitution p.Cys427Cys but in fact creates
a cryptic splice donor site in exon 16 leading to an aberrant
splicing and the deletion of 19 nucleotides in exon 16 con-
ﬁrmed by mRNA analysis (data not shown).4. Discussion
We have reported data on 15 COLQ-mutant CMS fol-
lowed up, over 10 years on average (Table 2). At the end
of our study, 80% of patients were ambulant without lim-
ited area and 87% of patients did not need any assistance
to breathe. However, relapses lasting up to several years
have been reported in our whole cohort. They were charac-
terized by worsening of muscle weakness with or without
bulbar signs. Puberty and pregnancy were identiﬁed as trig-
gering factors. In addiction, hormonal contraception treat-
ment or occurrence of the menopause stabilized or even
improved the clinical status highlighting the implication
of hormonal factors in the variability of symptoms in
COL Q-related CMS. Premenstrual syndrome and men-
struations has already been reported as triggering factor
of weakness worsening in myasthenia gravis [24]. Micro-
physiological study of endplate potentials in frog skeletal
muscle has suggested that progesterone can naturally mod-Fig. 2. Muscle biopsy from the deltoid muscle (A–C: 200). (A) Haematoxy
ATPase reaction at ph 9.4 showing type I ﬁber predominance. (C) Oil Red Oulate neuromuscular transmission through the raising of
acetylcholine esterase [25]. Worsening of muscle weakness
and increased jitter during menstruations were also
observed in a case of anti-MuSK positive female patient
[26].
Diagnosis was delayed in the whole cohort with a mean
age of 23 years after the onset of the symptoms which was
at 13 months of age on average. The mean age at the ﬁrst
examination was 19 years (3 to 48 years old), which may
explain the delay of the diagnosis. EMG carried out in
93% of our cohort, showed a double CMAP in response
to single nerve stimulus in all cases. This result allowed
us to avoid other congenital myasthenic syndromes with
mutations in RAPSN, CHAT and DOK7. Double CMAP
is characteristic but not speciﬁc of a Col Q related CMS. It
has also been observed in Slow-channel CMS [1]. However,
there is usually an autosomal dominant heredity except
rare cases of recessive Slow-channel CMS where onset of
symptoms is later in young adults [27].
We tried to determine if a correlation could be evidenced
between the phenotype and the genetic defect i.e., the nat-
ure of the mutation (null allele versus missense substitu-
tion) or the location of the mutation in the protein
domains. In our study, all patients but one (patient 2) pre-
senting two null alleles leading to an absence of proteinlin-eosin stain showing atrophic ﬁbers and variation in the ﬁber size. (B)
staining showing increased lipid droplets in muscle ﬁbers type II (arrows).
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one or two missense alleles, corroborating the data of prec-
edent studies [12]. No correlation could be clearly observed
between the location of the missense mutations within the
protein and the phenotype. Among COLQ mutated
patients, only the p.Tyr430Ser substitution (homozygous
in patient 11 and compound heterozygous in patient 5)
might be associated with later onset, a slow progression
and a relatively mild “limb-girdle” phenotype [9,12,21].
Another triggering factor of relapses identiﬁed was
potentially a treatment by esterase inhibitors corroborating
previous studies [8,9,15,19–21] whereas ephedrine had a
remarkable beneﬁt on muscle weakness and respiratory
function as in other reports [12,21–23]. This treatment
showed in a few days an improvement of the clinical status
in both cases: relapse or even progressive worsening.
Finally, in order to shorten the diagnostic delay and
avoid esterase inhibitors which could dramatically worsen
patients, we recommend an EMG with the study of the
neuromuscular transmission. Then, diagnosis will be easily
conﬁrmed by the molecular genetic analysis. Regarding to
the remarkable beneﬁt of ephedrine, we suggest the use of
this treatment at puberty or earlier in case of relapse.
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